Reuters logo
BRIEF-Regenxbio announces initiation of phase I/II clinical trial of RGX-501 for treatment of homozygous familial hypercholesterolemia
March 7, 2017 / 9:23 PM / 7 months ago

BRIEF-Regenxbio announces initiation of phase I/II clinical trial of RGX-501 for treatment of homozygous familial hypercholesterolemia

March 7 (Reuters) - Regenxbio Inc:

* Regenxbio announces initiation of phase i/ii clinical trial of rgx-501 for the treatment of homozygous familial hypercholesterolemia

* Regenxbio announces initiation of phase i/ii clinical trial of rgx-501 for the treatment of homozygous familial hypercholesterolemia

* Regenxbio inc - “we look forward to continuing enrollment, and expect to report interim trial results by end of 2017.” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below